Incidence and Associated Factors of SARS-CoV-2 Infection Post-mRNA-1273 Booster Vaccination in Health-Care Workers

Abstract

The COVID-19 pandemic has caused significant morbidity and mortality worldwide, especially among health-care workers. One of the most important preventive measures is vaccination. This study examined factors associated with the incidence rate of SARS-CoV-2 infection after mRNA-1273 booster vaccination (preceded by the CoronaVac primary vaccination) and the antibody profile of health-care workers at one of the tertiary hospitals in Indonesia. This was a combined retrospective cohort and cross-sectional study. Three hundred health-care workers who were given the mRNA-1273 booster vaccine a minimum of 5 months prior to this study were randomly selected. Participants were then interviewed about their history of COVID-19 vaccination, history of SARS-CoV-2 infection, and comorbidities. Blood samples were taken to assess IgG sRBD antibody levels. The median antibody level was found to be 659 BAU/mL (min 37 BAU/mL, max 5680 BAU/mL, QIR 822 BAU/mL) after the booster, and this was not related to age, sex, comorbidities, or adverse events following immunization (AEFI) after the booster. SARS-CoV-2 infection after the booster was correlated with higher antibody levels. In sum, 56 participants (18.6%) experienced SARS-CoV-2 infection after the mRNA-1273 booster vaccination within 5 months. Incidence per person per month was 3.2%. Age, sex, diabetes mellitus type 2, hypertension, obesity, and post-booster AEFI were not related to COVID-19 incidence after the booster. History of SARS-CoV-2 infection before the booster vaccination was significantly associated with a reduced risk of SARS-CoV-2 infection after booster vaccination, with a relative risk (RR) of 0.21 (95% CI 0.09–0.45, p < 0.001).

Analysis of COVID-19 Incidence and Protective Potential of Persisting IgG Class Antibodies against SARS-CoV-2 Infection in Hospital Staff in Poland

“…The results revealed no significant differences in the proportions of individuals who contracted COVID-19 based on sex or age. This is consistent with the findings of other studies on COVID-19 incidence among healthcare workers [ 37 ] but different from the findings of the studies concerning the general population, where males were reported to be more affected than females [ 38 ]. The lack of difference for healthcare workers can be attributed to their commonly high level of professional medical training that was indifferent to sex or age.…”

A Meta-Analysis on the Association between Peptic Ulcer Disease and COVID-19 Severity

“…To date, more than 200 COVID-19 vaccine candidates are in various stages of development, and more than 50 of these candidates have started clinical trials. These candidates may use inactivated or live attenuated viruses, nucleic acids (DNA or RNA), viral vectors, recombinant proteins or virus particles [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ]. WHO is committed to keeping the momentum for boosting access to COVID-19 vaccinations going and will continue to assist countries in expediting vaccine delivery in order to save lives and prevent people from becoming seriously ill.…”